Metastatic malignant melanoma and Neutrophil count decreased

Summary:

Neutrophil count decreased is found among people with Metastatic malignant melanoma, especially for people who are male, 60+ old.

The study analyzes which people have Neutrophil count decreased with Metastatic malignant melanoma. It is created by eHealthMe based on reports of 51 people who have Metastatic malignant melanoma from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Metastatic malignant melanoma?

Metastatic malignant melanoma (spreadable cancer tumour of melanine) is found to be associated with 237 drugs and 296 conditions by eHealthMe. Check the latest studies of Metastatic malignant melanoma.

What is Neutrophil count decreased?

Neutrophil count decreased (less than normal number of neutrophil a type of blood cell) is found to be associated with 1,416 drugs and 1,770 conditions by eHealthMe. Check the latest studies of Neutrophil count decreased.



On Aug, 07, 2026

51 people who have Metastatic Malignant Melanoma and Neutrophil Count Decreased are studied.

Would you have Neutrophil count decreased when you have Metastatic malignant melanoma?

Gender of people who have Metastatic Malignant Melanoma and experienced Neutrophil Count Decreased *:

  • female: 33.33 %
  • male: 66.67 %

Age of people who have Metastatic Malignant Melanoma and experienced Neutrophil Count Decreased *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 2.56 %
  • 20-29: 2.56 %
  • 30-39: 7.69 %
  • 40-49: 15.38 %
  • 50-59: 23.08 %
  • 60+: 48.72 %

Common co-existing conditions for these people *:

  1. High Blood Pressure: 6 people, 11.76%
  2. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 7.84%
  3. Metastases To Central Nervous System (cancer spreads to central nervous system): 4 people, 7.84%
  4. Pain: 4 people, 7.84%
  5. Metastases To Bone (cancer spreads to bone): 3 people, 5.88%
  6. Rashes (redness): 3 people, 5.88%
  7. Malignant Melanoma (skin cancer rises from melancytes): 3 people, 5.88%
  8. Nausea (feeling of having an urge to vomit): 2 people, 3.92%
  9. Back Pain: 2 people, 3.92%
  10. Mycobacterium Avium Complex Infection: 1 person, 1.96%

Common drugs taken by these people *:

  1. Carboplatin: 7 people, 13.73%
  2. Tafinlar: 6 people, 11.76%
  3. Afinitor: 5 people, 9.80%
  4. Taxol: 5 people, 9.80%
  5. Rivaroxaban: 4 people, 7.84%
  6. Calcium: 4 people, 7.84%
  7. Amlodipine: 4 people, 7.84%
  8. Keppra: 4 people, 7.84%
  9. Vitamin C: 3 people, 5.88%
  10. Opdivo: 3 people, 5.88%

Common symptoms for these people *:

  1. Thrombocytopenia (decrease of platelets in blood): 18 people, 35.29%
  2. White Blood Cell Count Decreased: 16 people, 31.37%
  3. Fever: 16 people, 31.37%
  4. Fatigue (feeling of tiredness): 13 people, 25.49%
  5. Diarrhea: 12 people, 23.53%
  6. Weakness: 9 people, 17.65%
  7. Lymphocyte Count Decreased: 9 people, 17.65%
  8. Anaemia (lack of blood): 8 people, 15.69%
  9. Dehydration (dryness resulting from the removal of water): 8 people, 15.69%
  10. Itching: 8 people, 15.69%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Neutrophil count decreased?

- Check whether Neutrophil count decreased is associated with a drug or a condition


Related studies:

Treatments, associated drugs and conditions:

All the drugs that are associated with Neutrophil count decreased:

All the conditions that are associated with Neutrophil count decreased:


How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Neutrophil count decreased and Metastatic malignant melanoma, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: